Noticias y Actividades de Immune-Onc Therapeutics
Ejecutivos
Ver el organigrama con sus 13 ejecutivos principales
Biografías más buscadas en Immune-Onc Therapeutics
- Charlene Liao, Director, President and Chief Executive Officer
- Barbara Klencke, Director
- Jack Donahue, Director
Recientes movimientos de ejecutivos en Immune-Onc Therapeutics
- Paolo Fundaro, se ha incorporado a la empresa como Director (noticia publicada el 21 de marzo de 2025).
- Mona Flores, se ha incorporado a la empresa como Director (noticia publicada el 21 de marzo de 2025).
Crear su alerta
para seguir los movimientos de los ejecutivos en Immune-Onc Therapeutics.
Biotecnología
Immune-Onc Therapeutics tiene 2.351 competidores entre los que se incluyen Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) y Lonza (Suiza).
Popular M&A news in Biotecnología
- BioNTech has announced the acquisition of CureVac (publicado el 12 de junio de 2025).
- SpliceBio acaba de anunciar una recaudación de fondos de 135 millones de dólares. (publicado el 11 de junio de 2025).
- Antares Therapeutics acaba de anunciar una recaudación de fondos de 177 millones de dólares. (publicado el 11 de junio de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Immune-Onc Therapeutics
- Here are some recent breakthroughs by women-led life sciences companies in the Bay Area - San Francisco Business Times
- Here are six major breakthroughs achieved by Bay Area women-led biotechs - San Francisco Business Times
- Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting — Immune-Onc Therapeutics
- Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting — Immune-Onc Therapeutics
- Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the AACR 2022 Annual Meeting — Immune-Onc Therapeutics
- News — Immune-Onc Therapeutics
- LLS TAP announces five new investments supporting next generation immunotherapies | Leukemia and Lymphoma Society
- Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the AACR 2022 Annual Meeting — Immune-Onc Therapeutics
- Press Release — Immune-Onc Therapeutics
- LLS TAP Announces Five New Investments Supporting Next Generation Immunotherapies | Leukemia and Lymphoma Society
- View more press releases Close
Redes sociales sobre Immune-Onc Therapeutics
- Immune-Onc Therapeutics en Wikipedia, Google News y Yahoo Finance
- Immune-Onc Therapeutics en LinkedIn, Twitter y YouTube
